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cell–extracellular matrix (ECM) inter-
actions, as well as targeted delivery 
of therapeutic agents.[9–12] Common 
methods used to achieve polymer cell 
surface engineering have employed cova-
lent strategies, via conjugation to amines 
or thiols, physical approaches, including 
electrostatic interactions and insertion 
through the phospholipid structure, 
or metabolic labeling.[2,5] The potential 
advances enabled by cell engineering 
approaches include the development of 
cell-based therapies, targeted delivery of 
drugs and imaging agents, recruitment 
of bioactive molecules, masking of cell 
surface agents, and control over cell–
environment interactions.[5,13]
Although cell engineering with polymers is undoubtedly a 
promising field, cell surface manipulation is a challenging tech-
nique that requires careful consideration of cell engineering 
chemistries to achieve a successful and stable conjugation of 
materials. Herein, the chemistries adopted for the attachment of 
polymeric materials at the cell surface will be evaluated, focusing 
on both single polymer chain attachment and delivery of poly-
meric nanoparticles. Importantly, cell response to the materials 
and therapeutic potential of the cell engineering approaches will 
be highlighted and future directions in the field discussed.
2. Noncovalent Strategies
Noncovalent conjugation of macromolecules offers a versatile 
and facile approach to introduce modification at the cell mem-
brane without perturbing cell physiology, and with minimal 
interference with cell behavior. The design of cytocompatible 
methodologies for cell engineering through physical conjuga-
tion of polymer chains has significantly evolved over the past 
few decades, providing a noninvasive strategy to decorate the 
cell membrane with synthetic polymers. However, several chal-
lenges, including achievement of stability over polymer conju-
gation and high grafting density, still need to be addressed.
2.1. Electrostatic Interactions
Physical conjugation of polymers by electrostatic interac-
tions is an attractive strategy that takes advantage of the neg-
ative charge present at the cell surface, as a result of sialic 
acid residues at the cell membrane.[14] Multiple layer-by-layer 
Manipulating the surface of living cells represents a powerful tool by which to 
control cell behavior and provides a unique strategy to modulate cellular func-
tion and cell–cell interactions. Recent progress in this area has seen the develop-
ment of robust and elegant approaches to selectively decorate the cell surface, 
leading to unprecedented advances in cellular manipulation and cell-based 
therapies. Despite some impressive in vitro results, several obstacles remain 
to the broader application of some of these strategies, including their limited 
translation in vivo. In this review, the leading techniques used to introduce 
polymers at the plasma membrane of mammalian cells are discussed, focusing 
on strategies that generate a stable and homogeneous distribution of polymeric 
chains at the cell surface. Application of these strategies to control cell behavior 
and deliver cell-based therapies to targeted tissues are highlighted.
1. Introduction
The cell membrane is an incredibly sophisticated environ-
ment, the complex composition of which regulates the variety 
of chemical and physical processes that occur inside and out-
side the cell.[1] A wide range of reactive functional groups, 
including amines, thiols, and carbonyls, offer great opportu-
nities for conjugation of exogenous molecules.[2] Introducing 
functionalities such as small molecules, proteins, peptides, 
polymers, and nanoparticles in such a diverse environment 
provides an excellent platform to manipulate cell behavior.[3–5] 
In the past few decades, cell engineering has endowed sci-
entists with new routes for the development of drug delivery 
systems, cell-based therapies, and biomaterials for tissue engi-
neering.[6–8] Recent developments in polymer conjugation to 
the cell membrane have allowed modification of cell–cell and 
© 2020 The Authors. Published by Wiley-VCH GmbH. This is an 
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approaches have been used to coat the cell membrane with 
positively charged polymers, including poly(l-lysine) (PLL), 
poly(styrene sulfonate) (PSS), poly(allylamine hydrochloride) 
(PAH), and poly(ethylenimine) (PEI).[15] The layer-by-layer 
deposition method, introduced over 20 years ago, consists in 
the alternate adsorption of polyelectrolytes that self-organize 
on the cell surface, leading to the formation of polyelectrolyte 
multilayer (PEM) films.[15] Layer-by-layer assembly of PEM 
films has emerged as a versatile surface engineering approach, 
representing a powerful tool to increase the plethora of avail-
able cell surface modifications. The feasibility of multi-layer-
by-layer approaches has been proved in rodent and pig islets, 
with encouraging in vitro and in vivo results.[16] Kozlovskaya 
et  al. used hydrogen-bonded interactions of a natural poly-
phenol (tannic acid) with poly(N-vinylpyrrolidone) deposited 
on the human islet surface by nonionic layer-by-layer assembly, 
showing that in vitro cell viability and function could be main-
tained for a few days.[17] In another study, PAH and PSS sodium 
salts were alternatively deposited on human islets forming a 
nanocoating that ensured in vitro preservation of β-cell struc-
ture and function. Moreover, protection against anti-glutamic 
acid decarboxylase (anti-GAD) antibody recognition was 
achieved, demonstrating this approach can be used to create 
a multifunctional capsule for immune protection of pancreatic 
islets.[18] Alternatively, a combination of cationic polymers and 
poly(ethylene glycol) (PEG) spacers has also been used to engi-
neer the cell membrane through electrostatic interactions. The 
use of PEG offers the advantage to introduce a polymer spacer 
between the cell surface and the positively charged polymers, 
hence reducing the risk of cytotoxicity.[19–22] In an exemplary 
study, Wilson et al. reported the first example of in vivo trans-
plantation of PEG-g-PLL coated pancreatic islets (Figure 1).[23,24] 
In order to build multiple layers, alginate, a natural and bio-
compatible poly saccharide, was used as the polyanionic species 
that inserts in between the PLL layers, enabling a film growth 
around pancreatic islets that does not affect biocompatibility 
and insulin production.
Layer-by-layer PEM deposition was also used to induce 
immunocamouflage in red blood cells (RBCs).[24,25] In this case, 
the polyelectrolyte sets were made of three nontoxic and biode-
gradable polymers: alginate, chitosan-graft-phosphorylcholine, 
and PLL–PEG. RBCs functionalized with this methodology 
exhibited high longevity in vivo and did not provoke immuno-
genic responses.[25]
Polyelectrolyte multilayer coatings have also been used to 
encapsulate mouse mesenchymal stem cells (MSCs) within 
polymeric shells consisting of hyaluronic acid and PLL. This 
strategy was investigated to provide new means for harvesting 
MSCs and successfully achieving their transplantation as intact, 
cohesive sheets into diseased tissues.[26] More broadly, this 
approach opens the possibility to broaden the scope and appli-
cation of PEM film coating to develop new opportunities in cell-
based therapeutics for tissue engineering applications.
2.2. Hydrophobic Insertion into the Cell Membrane
Originally pioneered by Chung et  al. while investigating the 
effect of lipid–PEG concentration and lipid chain length on the 
stability of polymer conjugation at the cell membrane, lipid–lipid 
interactions have since been used as a powerful tool to manipu-
late the cell membrane using a less invasive approach, by simply 
inserting polymers and therapeutics through the phospholipid 
layer.[27,28] PEG conjugation at the erythrocyte membrane was 
more durable with a longer lipid linker and when more than one 
lipid chain was conjugated to the polymer. Compared to covalent 
modification or electrostatic interactions, this approach is con-
sidered less harmful and more cytocompatible.[28]
Teramura et  al. reported the microencapsulation of pancre-
atic islets using poly(vinylalcohol) (PVA) anchored to a PEG-
phospholipid conjugate bearing a maleimide group (Mal–PEG–
lipid).[29–31] The advantage of using thiol–maleimide chemistry 
for polymer conjugation relies on the relatively mild reaction 
conditions that allow effective and rapid functionalization at 
Figure 1. Cell-surface-supported PEM films. A) Scheme illustrating that PLL-g-PEG copolymers can be used for layer-by-layer self-assembly of PEM 
films directly on the surface of cells comprising a pancreatic islet. Alginate, a natural and biocompatible polysaccharide, was chosen as the polyanionic 
species. B) Confocal and bright field microscopic images of pancreatic islets stained with calcein AM (green, viable) and ethidium homodimer (red, 
nonviable) after incubation with PLL and PLL-g-PEG copolymers with variable degrees of PEG grafting. Reproduced with permission.[24] Copyright 2011, 
American Chemical Society.
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physiological pH.[32,33] The Mal–PEG–lipid analog was first 
used to coat the cell surface, where the lipid is used to immobi-
lize PEG chains through the hydrophobic interaction between 
the lipid bilayer of the plasma membrane and the PEG–lipid 
conjugate. A PVA derivative functionalized with thiol groups 
was then used to create a first PVA layer on top of the PEG, 
and subsequent PVA layers were added by forming disulfide 
bonds between PVA chains. This strategy allowed for the 
encapsulation of pancreatic islets by forming an ultrathin layer-
by-layer PVA membrane, and thus represents a simple method 
to reduce immune response in islet transplantation. Notably, 
when single cells were treated with this methodology, cell via-
bility was heavily compromised. However, when islets were 
treated using the two polymers conjugates (both PEG and PVA), 
no difference in cell viability or cell function was observed. 
In a following report, hydrophobic insertion was also used to 
immobilize Mal–PEG–lipid analogs on islet surfaces followed 
by urokinase and thrombomodulin binding through thiol–
maleimide chemistry. No impair in insulin release in response 
to glucose stimulation was recorded after islet surface modifica-
tion. Moreover, the activity of urokinase and thrombomodulin 
was maintained, hence helping in preventing thrombus forma-
tion on the surface of pancreatic islets (Figure 2A).[34]
Hydrophobic insertion as a means to engineer the cell sur-
face has not only been used for immunocamouflage. Bertozzi 
and co-workers developed a strategy, glycocalyx, to introduce 
synthetic glycopolymers at the cell surface, designed to mimic 
native cell surface mucin glycoproteins.[35] Once in the cell sur-
face environment, these polymers exhibit behaviors similar to 
native mucins, such as specific protein binding and internaliza-
tion through endocytic pathways. This same strategy was also 
employed to provide a mechanistic understanding of the corre-
lation between hypersialylation and immunoprotection, which 
is a characteristic of many tumor types.[36] The introduction of 
sialylated glycopolymers onto Jurkat cells, CD34+ hematopoi-
etic stem cells (HSCs), and pig aortic epithelial cells enabled 
recruitment of a tyrosine-based motif able to attenuate natural 
killer cell response.
Huang et  al. used hydrophobic insertion to anchor syn-
thetic neoproteoglycans (neoPGs) on the surface of mouse 
embryonic stem cells (ESCs), resulting in an enhanced cell 
affinity for the fibroblast growth factor 2 (FGF2). The binding 
of ESC to FGF2 directed ESC differentiation toward a neural 
phenotype. This represents an important example where cell 
engineering was used to direct cell differentiation, and the ver-
satility of this technology makes it widely applicable to other 
types of differentiation.[37] Similarly, rat neural cells were modi-
fied with chondroitin sulfate (CS) glycosaminoglycans (CS 
GAGs), using liposomes functionalized with a ketone handle 
for appending the glycans via oxime chemistry. Liposomes 
fused with the lipidic membrane were able to enhance nerve 
growth-factor-mediated signaling and promote neural growth. 
Moreover, glycan surface density as well as specific structure 
could be precisely controlled (Figure 2B).[38] In another attempt 
to engineer stem cells with polymers, bioactive hyperbranched 
polyglycerol (HPG) conjugated to vasculature binding peptides 
was covalently modified with octadecyl chains for hydrophobic 
insertion in MSCs.[39] Tuning the number of octadecyl chains 
linked to the HPG allowed for control over the binding affinity 
of HPG to cells. HPG could noninvasively associate with stem 
cells to yield a cell-based therapy targeted toward defective 
vascular endothelium. The bioactive polymer coating signifi-
cantly enhanced the cellular affinity for the vascular endothelial 
adhesion molecule, a protein overexpressed in inflamed blood 
vessels.
3. Nonspecific Covalent Binding
While physical interaction might offer noninvasive approaches 
to coat the cell membrane with polymers, covalent binding 
has the potential to provide a more stable and durable conju-
gation. The cell surface is a heterogeneous and dynamic envi-
ronment that presents different functional groups available 
for the conjugation of macromolecules. Among these, primary 
amine groups from lysine residues are the most used for direct 
covalent attachment of polymers, proteins, peptides, and even 
small molecules.[3] While cysteine residues are also available at 
the cell surface, their thiol side chains are normally oxidized to 
disulfides, hence limiting their availability for polymer conju-
gation.[40] Covalent conjugation of polymers is often preferred 
as it offers a simple, straightforward solution to engineer the 
cell membrane compared to genetic manipulation. However, 
its lack of specificity can potentially affect cell morphology and 
functionality and induce cell apoptosis, hence limiting the use 
of this approach for some applications.
In order to react with amines present at the cell surface, 
macromolecules can be activated with a cyanuric chloride 
group or a N-hydroxysuccinimide (NHS) functionality. One 
of the first examples of cell engineering with polymers was 
reported by Chen and Scott, where RBCs were coated with 
methoxy-PEG (mPEG) activated with a cyanuric chloride reac-
tive group.[41,42] This strategy was used to physically shield 
RBCs from recognition from the immune system by reducing 
antibody binding to receptors at the cell surface.[43,44] The 
immunocamouflage provided by the presence of PEG chains 
around RBCs was proved to be effective not only in vitro but 
also in vivo.[45,46] Sheep RBCs modified with mPEG were trans-
fused in mice and demonstrated normal in vivo survival with 
no immunogenicity associated with the mPEG-modified RBCs. 
This strategy was envisaged to be useful in reducing the inci-
dence and severity of transfusion reactions.[47] While these are 
not very frequent (1 in 6000) when transfusions are required 
occasionally, 20–30% of chronically transfused individuals will 
eventually show evidence of alloimmunization against minor 
blood group antigens, making subsequent transfusions more 
problematic.[48] Moreover, engineering RBCs with PEG chains 
can help to prevent immune reactions in patients with auto-
immune hemolytic disease or in those suffering severe trauma 
where their matching blood type is not available. Interestingly, 
the same group investigated the effect of changing the chem-
istry of the linker used to attach mPEG to RBCs and the effect 
of changing the size of the polymer graft. Cyanuric chloride 
was determined to be the most efficient functionality to achieve 
a high level of functionalization in the shortest reaction time 
compared to benzotriazole carbonate and NHS ester. Moreover, 
it was found that a higher-molecular-weight PEG (20 kDa com-
pared to 2 or 5  kDa) could achieve a higher grafting density 
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2000302 (4 of 11)
www.advancedsciencenews.com www.mrc-journal.de
© 2020 The Authors. Published by Wiley-VCH GmbH
at the cell surface, hence enhancing the immunocamouflage 
effect.[46] Overall, the grafting efficiency, linker chemistry, and 
length, as well as molecular weight and density of the mPEG 
conjugation are essential parameters to consider in cell engi-
neering for immunocamouflage purposes.[46] Further studies 
explored the ability of the immunocamouflage to be extended 
beyond the application to blood transfusions to include, more 
broadly, any guest–host immune response.[47,49,50] Immune-
mediated response to tissue scaffolds or donor organs typi-
cally triggers the activation of T lymphocytes. By modifying the 
amine groups at the surface of T cells with mPEG conjugated 
through cyanuric chloride, T-cell activation could be minimized 
in order to significantly limit the host recognition and trigger 
a cascade immune response while compared to unmodified T 
cells.[49]
While cyanuric chloride was first widely used to engineer 
mammalian cells owing to its efficiency of conjugation and 
rapid reaction, its toxicity effects soon prompted for other 
mild and cytocompatible chemistries to be investigated. NHS 
was introduced as an alternative linker that readily reacts with 
Figure 2. Cell engineering through hydrophobic insertion. A) Schematic illustration of immobilization of protein onto the cell surface through Mal–PEG–
lipid. Thiol groups on the protein can react with maleimide groups at the end of PEG chains on the cell membrane. Reproduced with permission.[34] 
Copyright 2011, Elsevier. B) Neural cells modified with chondroitin sulfate (CS) glycosaminoglycans using liposomes that fuse with the cell membrane. CS 
GAGs were used to control nerve growth-factor-mediated signaling and promote neural growth. Reproduced with permission.[38] Copyright 2014, American 
Chemical Society.
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primary amine sites at the cell membrane. While this offered 
a more cytocompatible approach, a major drawback of cell 
coating with PEG was caused by poor association of the hydro-
philic macromolecules with cell surfaces. In response to this, 
Rossi et  al. developed a highly efficient, universal strategy in 
which nonreactive “additive” macromolecules, such as dextran 
or HPG, were used to modulate the grafting efficiency of cell 
surface reactive macromolecules. Unprecedented enhanced cell 
surface modifications by up to tenfold were observed when var-
ious concentrations of a suitable “additive” polymer were added 
with a constant and low concentration of a “reactive” macro-
molecule (Figure 3).[51]
In an attempt to provide an alternative to PEG, previously 
shown to trigger the production of anti-PEG antibodies,[52–54] 
hyperbranched polyglycerol was used to engineer the RBCs’ 
surface, providing an effective method for immunocamou-
flage. Similarly to PEG, HPG coating was successfully able to 
shield antigens at the surface of RBCs, providing a significant 
reduction in the level of antibody binding to cells. Moreover, 
the level of immunocamouflage offered by HPG was signifi-
cantly higher compared to PEG chains of similar molecular 
weight.[51,55,56]
More recently, NHS–amine coupling was used as a strategy 
to coat pancreatic islets with a heparin-incorporated starPEG 
nanofilm.[57] Heparin, a highly sulfated glycosaminoglycan with 
anti-inflammatory and anticoagulant properties, was incorpo-
rated for its ability to facilitate islet vascularization by recruiting 
pro-angiogenic growth factors. This approach of living cell sur-
face engineering demonstrated high cytocompatibility without 
negative consequences on cell viability and damage to cell 
morphology or function. More importantly, the heparin–PEG 
coating was also able to reduce instant blood-mediated inflam-
matory reaction, which typically occurs in intraportal islet trans-
plantation, while facilitating islet survival in a pro-inflammatory 
environment.[57,58] In a second report, heparin was replaced 
with CS, which possesses a strong binding affinity toward mul-
tiple growth factors and cytokines, and hence represents a pos-
sible means for incorporation of desirable biologically active 
factors through live cell engineering. CS–PEG coating at the 
surface of pancreatic islets resulted in enhanced in situ revas-
cularization that is protective against ECM disruption, while 
still alleviating immediate inflammatory reaction, blood coag-
ulation, and inflammation-related islet cell death. Since then, 
thrombomodulin was also used to engineer pancreatic islets 
through NHS–amine chemistry, where its presence resulted in 
a significant increase in the production of activated protein C 
and a reduction in islet-mediated thrombogenicity.[59,60] Algi-
nate- and PEG-based polymers, functionalized with azide and 
phosphine, respectively, which form spontaneous and chem-
oselective crosslinks via the bio-orthogonal Staudinger ligation, 
were conjugated to pancreatic cells through amine–NHS cou-
pling.[61] The resulting coatings were nontoxic, with unaffected 
glucose-stimulated insulin secretion.
4. Covalent Conjugation Using Bio-Orthogonal 
Chemistry
The manipulation of functional groups already present at the 
cell surface has been for a long time a preferred strategy in cell 
engineering, owing to the easy conjugation and abundance of 
reactive groups. However, direct covalent modification of the 
proteins at the cell cytoskeleton can substantially affect cell 
viability and normal cell function, while hydrophobic insertion 
does not offer a permanent surface modification, with lipid–
polymer conjugates rapidly dissociating from cells.[37,62,63] On 
the other end, introduction of bio-orthogonal functionalities 
at the cell membrane offers clear advantages over nonspecific 
polymer conjugation, including better cytocompatibility and 
stability of conjugation.[64–66] The cell surface repertoire can 
be expanded to include abiotic functionality through the bio-
synthetic introduction of unnatural sugars into cellular gly-
cans, a process termed metabolic oligosaccharide engineering 
(MOE).[13,67,68] This method was pioneered by Bertozzi and co-
workers and allows easy incorporation of bio-orthogonal han-
dles in vitro and in vivo.[69–71]
Shi et al. engineered MCF-7 human breast cancer cells using 
N-azidoacetylgalactosamine (Ac4GalNAz) to enrich cell surface 
glycoconjugates with an azide tag. Subsequent conjugation to 
a β-cyclodextrin (β-CD) through an azo–PEG–azo functional 
linker enabled controlled display of functional components 
Figure 3. Enhanced cell surface polymer grafting in the presence of a 
nonreactive polymer additive. A) Representation of cell surface modifica-
tion using primary amine reactive polymers. B) Cell compatible surface 
grafting process in the presence of a nonreactive polymer additive. Repro-
duced with permission.[51] Copyright 2010, American Chemical Society.
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through cell–cell interactions. The azo–PEG–azo crosslinking 
agent was used to induce adhesion and aggregation of β-CD-
modified cells and could be reversibly manipulated with UV 
light irradiation.[72]
Using N-azidoacetylmannosamine tetraacetate (Ac4ManNAz), 
Gibson and co-workers introduced azide groups at the plasma 
membrane of adenocarcinomic human alveolar basal epithelial 
cells (A549). The bio-orthogonal functionality was then used to 
attach fluorescein-functionalized poly(N-hydroethyl acrylamide) 
(pHEAn) polymers through copper-free alkyne–azide cycloaddi-
tion. Polymers remained on the cell surface for over 24 h, and 
no reduction in cell viability was observed compared to the con-
trol group.[73] Moreover, by introducing polymers conjugated 
to biotin, streptavidin was selectively recruited at the cell sur-
face, highlighting the ability to use polymers to recruit binding 
agents (Figure 4A,B). In a follow-up report, it was shown that 
synthetic polymers installed at the surface of azide-labeled A549 
remained attached for over 72 h, even after multiple cell divi-
sion cycles.[74] Grafting density was also evaluated in this study, 
with longer polymer chains (degree of polymerization higher 
than 50) showing lower grafting density as a consequence of 
steric hindrance.
The introduction of bio-orthogonal azide groups using meta-
bolic glycan labeling has also been used to engineer live cells, 
through introduction of Ac4ManNAz, with antibody-recruiting 
polymers (ARPs).[75] For this purpose, pentafluorophenyl 
acrylate (PFPA) polymers functionalized with an octyl alkyne 
were introduced in Jurkat cells and used to immobilize 
anti-2,4-dinitrophenyl (DNP) antibodies on the cell surface 
(Figure  4C,D).[76] This concept was further extended to mouse 
4T1 spheroids, demonstrating good penetration into the azide-
labeled spheroids and binding to the surface of individual cells.
Importantly, MOE using Ac4ManNAz has been successfully 
achieved in vivo by injecting the modified oligosaccharides 
intraperitoneally[69,77] or intravenously using caged Ac4ManNAz 
derivatives for cellular uptake.[78,79]
5. Grafting Polymers from the Cell Surface
Traditionally, modification of the cell surface with polymers 
has been achieved by physical or chemical conjugation of pre-
formed materials.[71,80–83] However, grafting-to approaches are 
sometimes limited by low polymer grafting on the cell surface 
and the use of a large excess of reactive polymers for function-
alization.[51] To overcome these challenges, grafting polymer 
chains directly from the cell surface was introduced as a meth-
odology that could improve grafting density and site-specific 
polymer conjugation. Although this strategy is, in principle, 
promising, significant synthetic challenges, including the 
Figure 4. Metabolic engineering of mammalian cells with bio-orthogonal azide functional groups. A) Immobilization of dibenzocyclooctyne-function-
alized pHEAn-biotin to azido-functionalized A549 cells, followed by recruitment of Strepavidin-Cy3 (red). B) Confocal images of cells after streptavidin 
recruitment. Reproduced with permission.[73] Copyright 2014, American Chemical Society. C) Antibody recruiting polymer (ARP) concept. The glycocalyx 
of a target cancer cell is engineered with azides by metabolic labeling with an azido sugar. ARPs are then conjugated to the cell surface by cooper-free 
azide–alkyne cycloaddition. D) Confocal microscopy images of 4T1 mouse breast cancer spheroids, cultured with (left) or without (right) azido sugar 
and treated with PFPA polymers (red fluorescence) and AF488-anti-DNP (green fluorescence). Reproduced with permission.[75] Copyright 2019, Royal 
Chemical Society.
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cytotoxicity of most initiators, catalysts, and monomers, have 
limited progress in this area, with only two attempts of cell 
surface polymerization from mammalian cells reported so far. 
Hawker and co-workers reported the use of hydrophobic inser-
tion to insert chain transfer agents (CTAs) at the plasma mem-
brane of Jurkat cells.[84] Interestingly, this approach was selected 
to replace a covalent conjugation of CTAs to the primary 
amine groups at the cell surface which resulted in significant 
cell death. These CTAs were used to polymerize water-soluble 
cytocompatible monomers via visible-light-mediated photo-
induced electron transfer reversible addition–fragmentation 
(PET-RAFT). In this study, molecular weights up to 10  kDa 
were observed, using methoxy-PEG acrylamide-1k as the 
mono mer. The grafting-from approach was proved to achieve 
superior polymer grafting and increase chain density compared 
to grafting pre-synthesized polymers to the plasma membrane.
Following this, Qi et  al. developed an approach for a cyto-
compatible polymerization at the cell surface to cluster cell sur-
face receptors. An anti-CD20 aptamer-conjugated macromer 
was synthesized, which was then efficiently and stably intro-
duced onto the Raji cell surface via ligand–receptor interac-
tions. With the assistance of ammonium peroxysulfate as the 
initiator, the macromer bound onto the Raji cell surface polym-
erized, inducing the clustering of CD20 receptors, and thereby 
triggering cell apoptosis.[85] To a broader extent, this cell surface 
polymerization could be applied in modulating the fates and 
functions of other cells, especially those mediated by spatial dis-
tribution of cell surface receptors, such as T-cell activation.
6. Targeting Polymeric Nanoparticles at the Cell 
Surface
Polymeric nanoparticles have emerged as a promising tool in 
the biomedical field to deliver drugs and imaging agents to the 
targeted site, enhancing selectivity of therapeutics, increasing 
circulation lifetime and water solubility of drugs and imaging 
agents.[86–90] Targeted delivery technologies are essential to 
avoid side effects and decrease the administered dose of poten-
tially toxic therapeutics. However, current delivery methods 
are far from perfect and present substantial challenges that 
nanomedicine is still facing.[91,92] Cell engineering has recently 
appeared as a potential strategy that can be used to direct poly-
meric nanoparticles to the surface of engineered cells. Despite 
the clear challenges of this approach, above all the selective 
engineering of cells directly in vivo, this area of research has 
attracted increasing interest, offering a promising new direction 
for the delivery of both small molecules and larger therapeutics.
6.1. Covalent Conjugation of Nanoparticles through Thiols at 
the Cell Surface
Stephan et  al. used free thiol groups present at the surface 
of HSCs, as well as T and B cells, the only cell types with a 
sufficient free thiol content at the membrane, to conjugate 
drug-loaded nanoparticles via maleimide–thiol chemistry.[93] 
Nanoparticles in the size range of 100–300  nm were coated 
with phospholipids conjugated to maleimide and loaded 
with glycogen synthase kinase-3β, previously demonstrated 
to enhance HSC proliferation and cell viability following sys-
temic injection. The drug-loaded nanoparticles released the 
drug into the HSCs over the course of 7 days and demonstrated 
increased cell proliferation post-engraftment compared to con-
trol experiments. Moreover, nanoparticle conjugation to cells 
was achieved without toxicity or interference with intrinsic cell 
functions. Prolonged retention of the particles on the surfaces 
of donor cells enabled sustained drug release without concerns 
of premature degradation of the particle carrier or cargo. In a 
follow-up study, the authors reported the conjugation of syn-
thetic nanocarriers to the surface of T cells via maleimide–thiol 
chemistry. The surface-engineered lymphocytes delivered their 
therapeutic cargo, a small-molecule inhibitor of phosphatases 
that downregulate T-cell receptor activation in the synapse, to 
the tumor site in mice with advanced prostate cancer, leading 
to enhanced survival rate.[94] PEG–PLL protein-based nanogels 
were also synthesized to anchor the T-cell surface through 
thiol–maleimide chemistry. A disulfide-containing bis-N-hy-
droxy succinimide crosslinker (NHS–SS–NHS) was used to 
incorporate in the nanogel many copies of the same protein 
crosslinked to itself. The disulfide crosslinker was specifically 
designed to be cleaved in response to reducing conditions at 
the surface of T cells, releasing the protein cargo composed 
of interleukin (IL)–2Fc (a fusion protein between IL-2 and an 
antibody Fc fragment) and ALT-803, a human IL-15 superag-
onist complex. The nanogel delivery selectively enhanced T-cell 
response in vivo and allowed higher doses of cytokine to be 
administered without toxicity, compared to free cytokine admin-
istration.[95] This approach was then extended to the delivery of 
IL-2 in vivo, improving the efficacy of this therapy against mela-
noma metastases.[96]
6.2. Conjugation of Nanoparticles through Bio-Orthogonal 
Functionalities
Together with the bio-orthogonal strategies mentioned earlier, 
aldehydes have also been investigated for cell surface engi-
neering, owing to their ability to react through Schiff base for-
mation with primary amines at the cell membrane. This strategy 
has been used for drug delivery and cell surface manipulation 
through mild oxidation of sialic acid residues. To this end, 
Yang and co-workers reported a novel drug delivery vehicle by 
hybridizing macrophages with nanoparticles through cell sur-
face modification. They generated aldehyde reactive sites at the 
surface of RAW264.7 macrophages through oxidation of the cell 
membrane by sodium periodate. These were then reacted with 
the nanoparticle surface composed of poly(amidoamine) den-
drimers. Following this, a reducing agent, sodium cyanoboro-
hydride, was applied to reduce Schiff bases to stable secondary 
amine linkages. The distribution of nanoparticles on the cell 
surface was confirmed by fluorescence imaging and was found 
to be dependent on the stability of the linkages conjugating the 
nanoparticles to the cell surface. Overall, this approach dem-
onstrated that a higher drug concentration could be achieved 
using this strategy when compared with direct cell loading.[97]
The delivery of nanoparticles at the cell surface has also 
been investigated using biotin–avidin binding. Biotin is a 
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water-soluble B vitamin that binds tightly to the tetrameric pro-
tein avidin, with a dissociation constant, Kd, on the order of 10−15 
m, one of the strongest known protein–ligand interactions.[98,99] 
The high biotin–avidin affinity has provided researchers with a 
powerful tool that can be applied in the fields of biotechnology 
and biomedicine. Biotin- and avidin-terminated linkers have 
been designed to provide a variety of small molecules, poly-
mers, or proteins that can be used for functionalization.[100–102] 
It is important to note that streptavidin, a form of avidin syn-
thesized by certain strains of Streptomyces bacteria, can gen-
erate immune response in humans, while avidin derived from 
egg whites exhibits nonspecific binding in some applications. 
Hence, deglycosylated, neutral forms of avidin, such as Extra-
vidin,[103] NeutrAvidin,[104] and NeutraLite,[105] should be used to 
investigate the clinical translation. Deglau et  al. modified pri-
mary amine groups on coronary artery endothelial cells using 
NHS–PEG–biotin.[106] Targeted delivery to the damaged arteries 
was achieved using NeutrAvidin-coated polystyrene micro-
spheres, which were delivered over the endothelial monolayers 
under flow conditions that mimic arterial shear stress.[107]
The metabolic glycoengineering approach described earlier 
for the conjugation of single polymer chains has also been 
applied to the delivery of drug-loaded nanoparticles to cells 
both in vitro and in vivo. Through metabolic glycoengineering, 
unnatural glycans are introduced onto cells by feeding specific 
precursors on the basis of their intrinsic metabolism. There-
fore, bio-orthogonal chemical reactions can occur specifically on 
target living cells with artificially introduced unnatural glycans 
containing particular chemical groups.[108] Koo et al. developed 
a strategy to introduce nanoparticles on the cell surface through 
bio-orthogonal copper-free click chemistry in vivo. Nanosized 
PEGylated liposomes modified with dibenzyl cyclooctyne 
(DABCO-lipo) were intravenously injected into tumor-bearing 
mice, prior to exposure in cancer cells of unnatural sialic acids 
containing azide groups through intratumoral injection of 
Ac4ManNAz.[109] This in vivo targeting strategy could success-
fully enhance accumulation of nanoparticles at the tumor site, 
showing the feasibility of this approach for targeted intracellular 
drug delivery. In a second report from the same group, chitosan 
nanoparticles were used to directly accumulate Ac4ManNAz at 
the tumor site, taking advantage of the enhanced permeation 
and retention (EPR) effect.[110] Bicyclo[6.1.0]nonyne-modified 
glycol chitosan nanoparticles (BCN-CNPs) were also used to 
deliver imaging agents to human mesenchymal stem cells 
(hMSCs) in vitro through metabolic engineering of glycans 
with an azide functionality (Figure 5A).[111] Nano particles were 
internalized by hMSCs and successfully distributed through 
cell division. In vivo injection of Cy5.5-, gold-, and iron-
labeled hMSCs allowed noninvasive cell tracking for up to 
15 days through fluorescence imaging and magnetic resonance 
imaging, demonstrating that Ac4ManNAz labeling can be used 
for prolonged in vivo cell tracking (Figure 5B).
While azide groups have been primarily used to express 
functional groups at the cell membrane, as a consequence of 
their ability to react using bio-orthogonal, cytocompatible chem-
istry, N-levulinoylmannosamine (ManLev) was also used to 
introduce ketones at the cell surface.[112] 2-methacryloyloxyethyl 
phosphorylcholine (MPC) nanoparticles, functionalized with 
hydrazide groups, could be used to deliver anticancer agents 
to ManLev-engineered HeLa cells.[113] Release of doxorubicin or 
paclitaxel over 3 days of cell culture determined a reduction in 
cell viability of 60% and 50%, respectively. Nonspecific delivery 
Figure 5. Conjugation of nanoparticles to the cell surface through bio-orthogonal chemistry. A) Schematic illustration of stem cell labeling and tracking 
method with nanoparticles via metabolic glycoengineering and bio-orthogonal copper-free click chemistry. B) Top: Comparison of cell labeling efficiency 
of BCN–CNP–Cy5.5 between 1–3) control stem cells and 4–6) Ac4ManNAz-treated stem cells. Bottom: In vivo imaging of labeled hMSCs by optical 
imaging after subcutaneous transplantation with hMSCs prelabeled with Ac4ManNAz and BCN-CNP-Cy5.5. Reproduced with permission.[111] Copyright 
2017), Elsevier.
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of these nanoparticles to cells was effectively reduced because 
of the presence of MPC units, demonstrating the advantage of 
cell engineering.
7. Conclusion and Outlook
The ability to rationally and precisely manipulate the plasma 
membrane of mammalian cells has great potential to over-
come many of the challenges faced by conventional cellular 
therapies and provide innovative prospects in the field of bio-
technology.  Herein, strategies to conjugate linear polymeric 
chains and polymer-based nanoparticles at the cell membrane 
are discussed, covering both nonspecific and site-specific con-
jugation, and the advantages and disadvantages of each tech-
nique are highlighted. While noncovalent polymer conjugation 
has been widely explored in vitro and offers a noninvasive, 
cytocompatible approach to interface materials with cells, it has 
been limitedly applied in vivo to induce immunocamouflage in 
RBCs.[25] Covalent conjugation has been investigated as a better 
alternative to noncovalent binding, and has found application 
in reducing the immune response after transplants in vivo,[45–47] 
as well as in cancer therapy by directly targeting T cells and 
boosting the immune response toward tumors.[94–96] However, 
the lack of selectivity of covalent approaches that use func-
tional groups already present at the plasma membrane, such 
as amines and thiols, limits their applications in targeted cell 
therapies and increases their side effects. On the other hand, 
bio-orthogonal chemistries offer unique and highly biocom-
patible routes to explore mammalian cell surface engineering. 
These strategies have been widely exploited in vivo and repre-
sent a powerful tool by which to introduce polymers at the cell 
surface homogeneously.[71,109–111] Future research should focus 
toward exploring the potential offered by these chemistries in 
the development of new cell-based therapies and in the manip-
ulation of cell behavior through bio-orthogonal cell engineering 
approaches.
The emerging and evolving area of cell engineering offers 
significant opportunities to interface polymeric materials with 
biological components to manipulate cell behavior and direct 
cell function. However, important challenges need to be over-
come, predominantly linked to the stability of the polymer 
conjugation, control over polymer grafting density, and translat-
ability of the cell engineering approaches in vivo.
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